PhageBank™ Deployed in Texas Outbreak of Life-Threatening Carbapenem Resistant A. baumannii (CRAB) in COVID-19 Patients
Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced a deployment in Texas of its investigational PhageBank™ therapy in response to a deadly outbreak of secondary infections with carbapenem resistant Acinetobacter baumannii (CRAB) bacteria in COVID-19 patients. Mortality rates were more than two-fold higher in COVID-19 patients with secondary CRAB infection, versus 32% mortality in patients without secondary CRAB infections.
International Matchmaking Symposium 18 November 2020
Emerging Antimicrobials & Diagnostics in AMR 2020
4th AMR Insights International Symposium to provide an international online podium for emerging preventives, new antimicrobial strategies, microbial diagnostics and related (platform) technologies.